<DOC>
	<DOC>NCT00828919</DOC>
	<brief_summary>To allow continuation of treatment of patients experiencing benefit from AG 013736</brief_summary>
	<brief_title>Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial Patients who were receiving axitinib tablets at the time their previous trial ended Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous AG013736 protocol should be used to determine stable or responding disease). Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol Patients may not participate in this trial if the conditions for continuing treatment in the previous AG013736 protocol are not met</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>angi-angiogenic</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>